MTOR and non-small cell lung carcinoma: In 2009, researchers have tried this strategy, using everolimus, a mTOR inhibitor, and found that everolimus plus gefitinib induced a growth-inhibitory effect in gefitinib-resistant NSCLC cell lines[28].